Activated Charcoal

證據等級: L5

預測適應症: 10 個

Activated Charcoal: From Acute Poisoning Treatment to Jeune Syndrome Situs Inversus

One-Sentence Summary

Activated charcoal is a non-selective gastrointestinal adsorbent classically used as an emergency decontaminant in acute drug overdose and poisoning. The TxGNN model predicts it may be effective for Jeune Syndrome Situs Inversus (a rare ciliopathy causing skeletal dysplasia with visceral organ laterality defects), with a prediction score of 89.94%. However, this prediction is currently supported by 0 clinical trials and 0 publications, and the mechanistic rationale is considered biologically implausible — the prediction likely reflects a knowledge graph network artifact rather than a genuine therapeutic signal.

Quick Overview

Item	Content
Original Indication	Acute poisoning and drug overdose (GI decontamination)
Predicted New Indication	Jeune Syndrome Situs Inversus
TxGNN Prediction Score	89.94%
Evidence Level	L5
Singapore Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from the Evidence Pack. Based on known pharmacology, activated charcoal is a highly porous, non-absorbable carbon material that acts through physical adsorption in the gastrointestinal lumen. It binds drugs, toxins, and metabolic waste products, preventing or reducing systemic absorption. Its action is entirely confined to the gut — it is not itself absorbed, and it exerts no systemic molecular effects on cell signalling, gene expression, or organ development.

Jeune Syndrome Situs Inversus (also known as Asphyxiating Thoracic Dystrophy with situs inversus) is a rare autosomal recessive ciliopathy caused by mutations in genes encoding primary cilia structural or functional proteins (e.g., IFT80, DYNC2H1, CEP120). The disease manifests as severe thoracic cage hypoplasia, limb shortening, renal and hepatic involvement, and — in the situs inversus variant — failure of embryonic left-right axis determination due to defective ciliary motility in the node. It is a structural and genetic disorder arising from impaired ciliogenesis during embryonic development.

There is no known biological pathway by which a luminal gastrointestinal adsorbent could influence cilia function, embryonic axis determination, or skeletal morphogenesis. The TxGNN high score most likely reflects a non-specific network connectivity artifact in the knowledge graph — for example, shared disease graph nodes related to "rare disease" or "metabolic toxin accumulation" — rather than a true repurposing signal. This prediction should not be taken as evidence of therapeutic potential.

Clinical Trial Evidence

Currently no related clinical trials registered for Activated Charcoal in Jeune Syndrome Situs Inversus.

Literature Evidence

Currently no related literature available for Activated Charcoal in Jeune Syndrome Situs Inversus.

Singapore Market Information

Activated charcoal currently has no registered products in Singapore. There are 0 authorisations on record.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Jeune Syndrome Situs Inversus is a genetic ciliopathy caused by mutations in cilia-related structural genes; activated charcoal's gastrointestinal adsorption mechanism has no plausible therapeutic pathway for this disease, and the evidence base is entirely absent (L5: model prediction only with no supporting clinical trials or publications).

To proceed, the following would be needed:

Identification of a biologically plausible mechanistic link between activated charcoal (or its downstream effects on gut-derived metabolites) and ciliary dysfunction or skeletal dysplasia — none is currently known
At minimum one peer-reviewed basic science or preclinical study demonstrating any effect on ciliogenesis or left-right axis patterning
Review of the TxGNN knowledge graph to determine whether the high prediction score arises from a network artifact (e.g., shared intermediate nodes unrelated to the target disease)
If a rationale is eventually identified, a formal safety profile and Singapore/international regulatory review would be required prior to any investigational use

Note: This report is for research reference only and does not constitute medical advice. All drug repurposing candidates require clinical validation before any therapeutic application. This content should be accompanied by a YMYL disclaimer on any public-facing platform.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.